Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice.
Recently, it has been shown that a new mutational pattern (the E44D/A and/or V118I mutation) confers moderate phenotypic lamivudine resistance in the absence of the M184V mutation. The E44D/A and/or the V118I mutation does not exist in drug-naive patients, and the prevalence increases with the number of treatment regimens and lamivudine experience. The mutations can preexist in nucleoside-experienced but lamivudine-naive patients. They are always associated with zidovudine resistance-associated mutations, even in the absence of M184V. These mutations are more stable than the M184V substitution during antiretroviral treatment interruptions.
Delaugerre
C
C
Department of Virology, Pitié-Salpêtrière Hospital, Paris, France.
Mouroux
M
M
Yvon-Groussin
A
A
Simon
A
A
Angleraud
F
F
Huraux
J M
JM
Agut
H
H
Katlama
C
C
Calvez
V
V
D000409:Alanine / Q000235:genetics; D019943:Amino Acid Substitution; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use; D001224:Aspartic Acid / Q000235:genetics; D004352:Drug Resistance, Microbial / Q000235:genetics; D005787:Gene Frequency; D018698:Glutamic Acid / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D007532:Isoleucine / Q000235:genetics; D009154:Mutation; D014633:Valine / Q000235:genetics
D019380:Anti-HIV Agents; D007532:Isoleucine; D001224:Aspartic Acid; D018698:Glutamic Acid; D054303:HIV Reverse Transcriptase; D014633:Valine; D000409:Alanine